BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32492700)

  • 1. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R; Asada S; Park SJ; Yokoyama A; Becker HJ; Kanai A; Visconte V; Hershberger C; Hayashi Y; Yonezawa T; Tamura M; Fukushima T; Tanaka Y; Fukuyama T; Matsumoto A; Yamasaki S; Nakai K; Yamazaki S; Inaba T; Shibata T; Inoue D; Honda H; Goyama S; Maciejewski JP; Kitamura T
    Blood; 2020 Oct; 136(14):1670-1684. PubMed ID: 32492700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia.
    Bera R; Chiu MC; Huang YJ; Lin TH; Kuo MC; Shih LY
    J Hematol Oncol; 2019 Oct; 12(1):104. PubMed ID: 31640815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
    Nagase R; Inoue D; Pastore A; Fujino T; Hou HA; Yamasaki N; Goyama S; Saika M; Kanai A; Sera Y; Horikawa S; Ota Y; Asada S; Hayashi Y; Kawabata KC; Takeda R; Tien HF; Honda H; Abdel-Wahab O; Kitamura T
    J Exp Med; 2018 Jun; 215(6):1729-1747. PubMed ID: 29643185
    [No Abstract]   [Full Text] [Related]  

  • 4. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S; Goyama S; Inoue D; Shikata S; Takeda R; Fukushima T; Yonezawa T; Fujino T; Hayashi Y; Kawabata KC; Fukuyama T; Tanaka Y; Yokoyama A; Yamazaki S; Kozuka-Hata H; Oyama M; Kojima S; Kawazu M; Mano H; Kitamura T
    Nat Commun; 2018 Jul; 9(1):2733. PubMed ID: 30013160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS.
    Inoue D; Kitaura J; Matsui H; Hou HA; Chou WC; Nagamachi A; Kawabata KC; Togami K; Nagase R; Horikawa S; Saika M; Micol JB; Hayashi Y; Harada Y; Harada H; Inaba T; Tien HF; Abdel-Wahab O; Kitamura T
    Leukemia; 2015 Apr; 29(4):847-57. PubMed ID: 25306901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.
    Yang H; Kurtenbach S; Guo Y; Lohse I; Durante MA; Li J; Li Z; Al-Ali H; Li L; Chen Z; Field MG; Zhang P; Chen S; Yamamoto S; Li Z; Zhou Y; Nimer SD; Harbour JW; Wahlestedt C; Xu M; Yang FC
    Blood; 2018 Jan; 131(3):328-341. PubMed ID: 29113963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O; Adli M; LaFave LM; Gao J; Hricik T; Shih AH; Pandey S; Patel JP; Chung YR; Koche R; Perna F; Zhao X; Taylor JE; Park CY; Carroll M; Melnick A; Nimer SD; Jaffe JD; Aifantis I; Bernstein BE; Levine RL
    Cancer Cell; 2012 Aug; 22(2):180-93. PubMed ID: 22897849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse model.
    Hsu YC; Chiu YC; Lin CC; Kuo YY; Hou HA; Tzeng YS; Kao CJ; Chuang PH; Tseng MH; Hsiao TH; Chou WC; Tien HF
    J Hematol Oncol; 2017 Jul; 10(1):139. PubMed ID: 28697759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S; Kitamura T
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-level GATA2 overexpression promotes myeloid progenitor self-renewal and blocks lymphoid differentiation in mice.
    Nandakumar SK; Johnson K; Throm SL; Pestina TI; Neale G; Persons DA
    Exp Hematol; 2015 Jul; 43(7):565-77.e1-10. PubMed ID: 25907033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway.
    Fujino T; Goyama S; Sugiura Y; Inoue D; Asada S; Yamasaki S; Matsumoto A; Yamaguchi K; Isobe Y; Tsuchiya A; Shikata S; Sato N; Morinaga H; Fukuyama T; Tanaka Y; Fukushima T; Takeda R; Yamamoto K; Honda H; Nishimura EK; Furukawa Y; Shibata T; Abdel-Wahab O; Suematsu M; Kitamura T
    Nat Commun; 2021 Mar; 12(1):1826. PubMed ID: 33758188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKL homeobox gene activities in normal and malignant myeloid cells.
    Nagel S; Scherr M; MacLeod RAF; Pommerenke C; Koeppel M; Meyer C; Kaufmann M; Dallmann I; Drexler HG
    PLoS One; 2019; 14(12):e0226212. PubMed ID: 31825998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukemogenic mechanisms and targets of a NUP98/HHEX fusion in acute myeloid leukemia.
    Jankovic D; Gorello P; Liu T; Ehret S; La Starza R; Desjobert C; Baty F; Brutsche M; Jayaraman PS; Santoro A; Mecucci C; Schwaller J
    Blood; 2008 Jun; 111(12):5672-82. PubMed ID: 18388181
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J; Chen Z; Chen C; Zhang M; Zhang Y; Song J; Yuan J; Jiang X; Xing W; Yang J; Bai J; Zhou Y
    Cancer Lett; 2021 Oct; 519():78-90. PubMed ID: 34186160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hhex induces promyelocyte self-renewal and cooperates with growth factor independence to cause myeloid leukemia in mice.
    Jackson JT; Ng AP; Shields BJ; Haupt S; Haupt Y; McCormack MP
    Blood Adv; 2018 Feb; 2(4):347-360. PubMed ID: 29453249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation.
    Brandts CH; Sargin B; Rode M; Biermann C; Lindtner B; Schwäble J; Buerger H; Müller-Tidow C; Choudhary C; McMahon M; Berdel WE; Serve H
    Cancer Res; 2005 Nov; 65(21):9643-50. PubMed ID: 16266983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Molecular mechanisms by which the mutant ASXL1/BAP1 complex aggravates myeloid leukemia].
    Asada S
    Rinsho Ketsueki; 2020; 61(4):392-405. PubMed ID: 32378586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9-mediated ASXL1 mutations in U937 cells disrupt myeloid differentiation.
    Wu ZJ; Zhao X; Banaszak LG; Gutierrez-Rodrigues F; Keyvanfar K; Gao SG; Quinones Raffo D; Kajigaya S; Young NS
    Int J Oncol; 2018 Apr; 52(4):1209-1223. PubMed ID: 29532865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1-BAP1 complex.
    Balasubramani A; Larjo A; Bassein JA; Chang X; Hastie RB; Togher SM; Lähdesmäki H; Rao A
    Nat Commun; 2015 Jun; 6():7307. PubMed ID: 26095772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-derived neomorphic mutations in ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcription network.
    Xia YK; Zeng YR; Zhang ML; Liu P; Liu F; Zhang H; He CX; Sun YP; Zhang JY; Zhang C; Song L; Ding C; Tang YJ; Yang Z; Yang C; Wang P; Guan KL; Xiong Y; Ye D
    Protein Cell; 2021 Jul; 12(7):557-577. PubMed ID: 32683582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.